Total Payments
$594,305
2024 Payments
$63,555
Companies
51
Transactions
583
Medicare Patients
469
Medicare Billing
$84,803
Payment Breakdown by Category
Consulting$467,896 (78.7%)
Other$85,261 (14.3%)
Travel$19,770 (3.3%)
Food & Beverage$18,553 (3.1%)
Research$2,750 (0.5%)
Education$75.99 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $467,896 | 174 | 78.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $55,900 | 16 | 9.4% |
| Honoraria | $29,361 | 9 | 4.9% |
| Travel and Lodging | $19,770 | 66 | 3.3% |
| Food and Beverage | $18,553 | 316 | 3.1% |
| Unspecified | $2,750 | 1 | 0.5% |
| Education | $75.99 | 1 | 0.0% |
Payments by Type
General
$591,555
582 transactions
Research
$2,750
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | $210,730 | 200 | $0 (2024) |
| GlaxoSmithKline, LLC. | $66,787 | 36 | $0 (2024) |
| Clovis Oncology, Inc. | $33,956 | 55 | $0 (2022) |
| Eisai Inc. | $33,069 | 15 | $0 (2024) |
| TESARO, Inc. | $32,983 | 57 | $0 (2019) |
| Aadi Bioscience, Inc. | $32,453 | 18 | $0 (2024) |
| AstraZeneca UK Limited | $28,245 | 9 | $0 (2024) |
| Merck Sharp & Dohme LLC | $18,933 | 30 | $0 (2024) |
| Genentech USA, Inc. | $18,856 | 19 | $0 (2019) |
| Alkermes, Inc. | $13,590 | 12 | $0 (2023) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $63,555 | 74 | AstraZeneca Pharmaceuticals LP ($12,396) |
| 2023 | $72,693 | 74 | Aadi Bioscience, Inc. ($23,616) |
| 2022 | $103,034 | 98 | AstraZeneca Pharmaceuticals LP ($39,999) |
| 2021 | $88,648 | 54 | AstraZeneca Pharmaceuticals LP ($44,244) |
| 2020 | $82,885 | 40 | AstraZeneca Pharmaceuticals LP ($41,035) |
| 2019 | $90,919 | 130 | AstraZeneca Pharmaceuticals LP ($33,314) |
| 2018 | $40,947 | 54 | AstraZeneca Pharmaceuticals LP ($18,193) |
| 2017 | $51,624 | 59 | Genentech USA, Inc. ($14,225) |
All Payment Transactions
583 individual payment records from CMS Open Payments — Page 1 of 24
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/30/2024 | GlaxoSmithKline, LLC. | ZEJULA (Drug) | Consulting Fee | Cash or cash equivalent | $2,400.00 | General |
| Category: ONCOLOGY | ||||||
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $122.05 | General |
| Category: Oncology | ||||||
| 12/19/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $17.02 | General |
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $35.79 | General |
| Category: Oncology | ||||||
| 12/18/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $15.34 | General |
| Category: Oncology | ||||||
| 12/06/2024 | Genmab U.S., Inc. | Epkinly (Drug) | Consulting Fee | In-kind items and services | $6,000.00 | General |
| Category: Oncology | ||||||
| 12/06/2024 | AstraZeneca Pharmaceuticals LP | — | Consulting Fee | Cash or cash equivalent | $1,370.00 | General |
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Consulting Fee | Cash or cash equivalent | $6,710.00 | General |
| 11/25/2024 | Merck Sharp & Dohme LLC | — | Travel and Lodging | Cash or cash equivalent | $150.00 | General |
| 11/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $65.00 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $57.49 | General |
| Category: ONCOLOGY | ||||||
| 11/15/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $54.99 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $560.87 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Travel and Lodging | In-kind items and services | $326.57 | General |
| Category: ONCOLOGY | ||||||
| 11/14/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $149.99 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 11/13/2024 | BeiGene USA, Inc. | — | Consulting Fee | Cash or cash equivalent | $1,950.00 | General |
| 11/08/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $22.51 | General |
| Category: Oncology | ||||||
| 11/06/2024 | AstraZeneca UK Limited | — | Consulting Fee | Cash or cash equivalent | $1,640.00 | General |
| 11/05/2024 | GlaxoSmithKline, LLC. | — | Consulting Fee | Cash or cash equivalent | $400.00 | General |
| 11/03/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $79.22 | General |
| Category: Oncology | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $20.55 | General |
| Category: Oncology | ||||||
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $15.48 | General |
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | — | Food and Beverage | In-kind items and services | $14.28 | General |
| 11/01/2024 | AstraZeneca Pharmaceuticals LP | LYNPARZA (Drug) | Food and Beverage | In-kind items and services | $13.63 | General |
| Category: Oncology | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 123 | 336 | $93,102 | $24,001 |
| 2022 | 4 | 124 | 304 | $66,200 | $22,211 |
| 2021 | 4 | 126 | 322 | $64,582 | $26,004 |
| 2020 | 3 | 96 | 211 | $41,009 | $12,587 |
Total Patients
469
Total Services
1,173
Medicare Billing
$84,803
Procedure Codes
15
All Medicare Procedures & Services
15 procedure records from CMS Medicare Utilization
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 74 | 278 | $77,419 | $18,845 | 24.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 21 | 21 | $6,432 | $2,080 | 32.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 13 | 17 | $5,563 | $1,781 | 32.0% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 15 | 20 | $3,688 | $1,295 | 35.1% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 79 | 224 | $48,342 | $15,724 | 32.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 14 | 43 | $7,033 | $2,409 | 34.3% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 14 | 20 | $5,853 | $2,248 | 38.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 17 | 17 | $4,972 | $1,830 | 36.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 67 | 212 | $38,781 | $16,161 | 41.7% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 21 | 44 | $11,314 | $4,761 | 42.1% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 16 | 44 | $7,762 | $2,698 | 34.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 22 | 22 | $6,725 | $2,383 | 35.4% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Facility | 2020 | 71 | 172 | $32,270 | $9,584 | 29.7% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 11 | 25 | $4,415 | $1,545 | 35.0% |
| 99204 | New patient office or other outpatient visit, typically 45 minutes | Facility | 2020 | 14 | 14 | $4,324 | $1,458 | 33.7% |
About Dr. Thomas Herzog, M.D
Dr. Thomas Herzog, M.D is a Gynecologic Oncology healthcare provider based in Cincinnati, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 07/07/2006. The National Provider Identifier (NPI) number assigned to this provider is 1619909850.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Thomas Herzog, M.D has received a total of $594,305 in payments from pharmaceutical and medical device companies, with $63,555 received in 2024. These payments were reported across 583 transactions from 51 companies. The most common payment nature is "Consulting Fee" ($467,896).
As a Medicare-enrolled provider, Herzog has provided services to 469 Medicare beneficiaries, totaling 1,173 services with total Medicare billing of $84,803. Data is available for 4 years (2020–2023), covering 15 distinct procedure/service records.
Ad
Practice Information
- Specialty Gynecologic Oncology
- Other Specialties Gynecologic Oncology
- Location Cincinnati, OH
- Active Since 07/07/2006
- Last Updated 02/24/2016
- Taxonomy Code 207VX0201X
- Entity Type Individual
- NPI Number 1619909850
Products in Payments
- LYNPARZA (Drug) $195,105
- Rubraca (Drug) $33,485
- Lenvima (Drug) $27,371
- Fyarro (Drug) $23,653
- Avastin (Biological) $21,496
- ZEJULA (Drug) $20,971
- YONDELIS (Drug) $13,261
- JEMPERLI (Biological) $11,467
- FYARRO (Drug) $6,462
- HEMOBLAST (Device) $6,253
- Epkinly (Drug) $6,026
- HemoBlast Bellows (Device) $5,511
- TUKYSA (Drug) $4,066
- Enhertu (Drug) $3,768
- ENSEAL Product Family (Device) $3,174
- MYCHOICE CDX (Device) $3,084
- TIVDAK (Biological) $2,985
- KIMMTRAK (Drug) $2,885
- Optune (Device) $2,400
- Dayvigo (Drug) $2,375
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Gynecologic Oncology Doctors in Cincinnati
Eric Eisenhauer, M.d, M.D
Gynecologic Oncology — Payments: $10,001
Gynecologic Oncology $10,001
Dr. Kevin Schuler, M.d, M.D
Gynecologic Oncology — Payments: $1,963
Gynecologic Oncology $1,963
Dr. Caroline Billingsley, M.d, M.D
Gynecologic Oncology — Payments: $969.74
Gynecologic Oncology $969.74
Jack Basil, Md, MD
Gynecologic Oncology — Payments: $487.09
Gynecologic Oncology $487.09
Dr. Nancy Simon, Md, MD
Gynecologic Oncology
Gynecologic Oncology
Dr. Nader Husseinzadeh, M.d, M.D
Gynecologic Oncology
Gynecologic Oncology